Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM Phase 3 trial of lisocabtagene maraleucel versus standard of care in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2018-000929-32Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mature B-cell lymphoma and aggressive B-cell lymphoma comparing Breyanzi with Standard of care (2 arms). Primary endpoint: Event-free survival. Started Apr 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
mature B-cell lymphomaaggressive B-cell lymphoma
Beyond the preview
Go deeper on 2018-000929-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000929-32.